Wet Age-Related Macular Degeneration
VIDEO: Subcutaneous injection shows promise for wet AMD, DME
FORT LAUDERDALE, Fla. — In this Healio Video Perspective, Michael A. Singer, MD, discusses promising results for migaldendranib for the treatment of wet age-related macular degeneration and diabetic macular edema.
Aflibercept 8 mg shows sustained improvements in wet AMD through 156 weeks
FORT LAUDERDALE, Fla. — Aflibercept 8 mg demonstrated sustained functional and anatomic improvements in patients with wet age-related macular degeneration through 156 weeks, according to a presenter.
In Case You Missed…Advancing Outcomes in Retinal Disease
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
FDA does not approve additional extended dosing intervals for Eylea HD
The FDA issued a complete response letter for a supplemental biologics license application, in which it did not approve extending the dosing intervals for Eylea HD, according to a press release from Regeneron.
Are new anti-VEGF agents beneficial for pigment epithelial detachment?
SEVILLE, Spain — Retinal pigment epithelial detachment is associated with neovascular age-related macular degeneration in 30% to 80% of cases, according to the literature.
Referral Criteria
Opthea discontinues development of sozinibercept in wet AMD
Opthea has discontinued development of sozinibercept in wet age-related macular degeneration, according to a press release.
Phase 3 COAST trial of wet AMD combination therapy misses primary endpoint
The phase 3 COAST trial investigating 2 mg sozinibercept for the treatment of wet age-related macular degeneration in combination with 2 mg aflibercept did not meet its primary endpoint, according to a press release from Opthea.
VIDEO: EYP-1901 shows noninferiority to aflibercept in wet AMD
KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Ashkan M. Abbey, MD, discusses 1-year results from the phase 2 DAVIO 2 clinical trial investigating EYP-1901 in previously treated wet age-related macular degeneration.
VIDEO: Duravyu for wet AMD shows similar outcomes to aflibercept
KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Ramiro Ribeiro, MD, PhD, of EyePoint Pharmaceuticals, discusses Duravyu, a vorolanib intravitreal insert.